Editas delays IND submission for LCA10

In its 1Q17 earnings report, Editas Medicine Inc. (NASDAQ:EDIT) said it delayed its target date to submit an IND for LCA10 from the end of 2017 to mid-2018. The preclinical CRISPR-based product is designed to treat Leber congenital amaurosis (LCA) type 10 by repairing a mutation in centrosomal protein 290kDa (CEP290)...